{"analyses":[{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.42","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8375","paramType":"Hazard Ratio (HR)","paramValue":"0.90","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval (CI) was not estimable due to an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.2","upperLimit":"NA","value":"11.2"},{"comment":"The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"5.6","upperLimit":"NA","value":"15.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"DOR was defined as the time from first occurrence of a documented confirmed objective response (CR or PR) to PD as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SODs must also demonstrate an absolute increase of ≥ 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"MEDIAN","populationDescription":"DOR-evaluable population included all participants with a measurable disease at baseline and a post-baseline confirmed objective response (CR or PR).","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months","title":"Part 2: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}